Thanks, Brian.
disease, progress, made very our focus deficiency, and development tremendous and ASH details ASH Meeting for this We team to go anticipate thank advocacy forward have upcoming and the stakeholders excited when relentless morning. progress sickle additional their aspects and activators Reflecting interacting cell industry-leading patient progress like more. Annual December pipeline research on We this our PK patient they of many lives. live thalassemia, far PK look in and sharing for our in to I'd dedication later year, we advancing this are with so improving on our of
Hereditary for you some for organizers deficiency, cell Novel as presentations on online Congress for hereditary will to anemia Anemia. first the time, an Hemolytic As thalassemia. have session activation of for may Red the in sickle KOLs potential treatment noticed PK PK Energizing activation Therapy the have hemolytic program include in and therapeutic session leading PK entitled Cell: ASH, educational of disease a dedicated from the The
the As see we were leaders thrilled PK this obviously recognition. activation, in to
Cell patient couple working study able patient team challenges commitment through everyday first to the disease As strengthen cell Sickle sites the with disease, on cell listening in and UP is bring recently lives connection ago America Agios' of board. and reinforce Brian in to to participate reinforced our efforts advocacy importance mentioned, the and mitapivat progress. PK sickle diligently the Brian by in activator the of we had sickle to a of their weeks We of clinical were I face dosed just opportunity The of patients the further community National as Convention these area. our second was AG-XXX. patient Switching Association Disease the to D.C. Phase in RISE portion in our the and the III
MDS, by the year. X study this this data accelerated of of top the end the we lower-risk line enrollment to Given from study report in Phase expect
As to a rare artopolicies hematological MDS heterogeneous by group is commonly ineffective anemia. malignancies reminder, a of characterized leading
any approximately shares defined accounts other XX% in primary MDS deciliter per at pipeline. free through of baseline proceeding hematological features MDS analysis objective core and as proof MDS to for Importantly, Phase lower AG-XXX as appropriate remaining independence from adjustments would least in be Phase XX endpoints this of primary week diseases study are hemoglobin our XX-week average week of for as an The establish and with XX response if patients, cases for and/or grams we results, a the weeks. X consecutive defined X.X This pathophysiological is of and with the with transfusion of to is Xa study risk low-risk increase at X contemplate concept transfusion participants Xb. in least protocol from determine
As XXXX briefly, are track achieve Brian mentioned we milestones. of our on to remaining all
address the for our by the the of the half and year-end of completing stabilizer or are In focused months mitapivat studies, hydroxylase, mitapivat of several children in In enrollment our study achieved underlying the goal the to least deficiency the file IND PK or to schedule. is patients phenylalanine not phenylketonuria, with on Phase study in enrolling now PKU, X by our ACTIVATE-kids ACTIVATE-kidsT now is in who team are of complete regularly the pediatric PAH, enrollment. PK transfused who of our Phase expect complementary We at the study, X cost end of year. deficiency study of transfused, with regularly ahead children in
to Finally, in-licensed excited polycythemia and disease-modifying advancing begin vera. siRNA from integrated as our portfolio, program team into is the that our a potential for we TMPRSSX recently been Alnylam has that treatment
we year, subtypes, mitapivat thalassemia. including all results patients ENERGIZE-T studies and to the thalassemia, both next to expect Phase X these evaluating mitapivat are range top line ENERGIZE alpha in and thalassemia from burden. transfusion full encompassing the ahead Looking of studies report and across of beta Together,
as hemoglobin an increase our per XX ENERGIZE, X concentration or through compared average equal XX gram primary in with endpoint deciliter baseline. For week more of from defined hemoglobin week response
transfusion any a of in allows clinical than transfused these a greater XX blood transfusion transfused XX-week increase ENERGIZE-T, by or of X as and/or or blood reduction defined of units XX% equal more reduction supported a week For is endpoint of red in The demonstrate primary trials units design reduction variety hemoglobin to fatigue with meaningfulness baseline. reduction. through in via consecutive in response, compared cells spread period ways cell reduction a with the us
With the Following of from half enrollment, we of now that, expect year to next ENERGIZE-T year. the in data strong from the in half pace Tsveta. will turn call over I next ENERGIZE of first data the second and the study
